Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction

Circulation

Volumn 131, Issue 12, 2015, Pages 1071-1081

  Zwadlo, Carolin ^a   Schmidtmann, Elisa ^a   Szaroszyk, Malgorzata ^a   Kattih, Badder ^a   Froese, Natali ^a   Hinz, Hebke ^a   Schmitto, Jan Dieter ^b   Widder, Julian ^a   Batkai, Sandor ^c   Bähre, Heike ^a   Kaever, Volkhard ^a   Thum, Thomas ^c,d   Bauersachs, Johann ^a   Heineke, Joerg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Leibniz Forschungslaboratorien für Biotechnologie und künstliche Organe   (Germany)

^c Institut für Molekulare und Translationale Therapiestrategien IMTTS   (Germany)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Heart failure; Hormones; Hypertrophy

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; PROTEIN KINASE B; STEROID 5ALPHA REDUCTASE; ANTIANDROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANDROGEN THERAPY; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART DILATATION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; NEWBORN; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ANDROGEN ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; FEMALE; FINASTERIDE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84929518647     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.012066     Document Type: Article

References (44)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600. doi: 10.1038/nrm1983.
3. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370-1380. doi: 10.1056/NEJMra072139.
4. Fraccarollo D, Galuppo P, Bauersachs J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc Res. 2012;94:293-303. doi: 10.1093/cvr/cvs109.
5. Luczak ED, Leinwand LA. Sex-based cardiac physiology. Annu Rev Physiol. 2009;71:1-18. doi: 10.1146/annurev.physiol.010908.163156.
6. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003;112:302-307. doi: 10.1172/JCI19429.
7. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256-261.
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
9. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW; WISDOM group. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335:239. doi: 10.1136/bmj.39266.425069.AD.
10. Sluijmer AV, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab. 1995;80:2163-2167. doi: 10.1210/jcem.80.7.7608272.
11. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol. 2008;29:169-181. doi: 10.1016/j.yfrne.2007.10.005.
12. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H1560-H1569. doi: 10.1152/ajpheart.01087.2002.
13. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem. 2005;280:29661-29666. doi: 10.1074/jbc.M411694200.
14. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology. 2012;79:1197-1205. doi: 10.1016/j. urology.2012.01.024.
15. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990;37:375-378.
16. Yamana K, Labrie F, Luu-The V. Human type 3 5-alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Invest. 2010;2:293-299.
17. Heineke J, Auger-Messier M, Correll RN, Xu J, Benard MJ, Yuan W, Drexler H, Parise LV, Molkentin JD. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med. 2010;16:872-879. doi: 10.1038/nm.2181.
18. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW 2nd. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121-8126.
19. Heineke J, Ruetten H, Willenbockel C, Gross SC, Naguib M, Schaefer A, Kempf T, Hilfiker-Kleiner D, Caroni P, Kraft T, Kaiser RA, Molkentin JD, Drexler H, Wollert KC. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A. 2005;102:1655-1660. doi: 10.1073/pnas.0405488102.
20. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103:670-677.
21. Koal T, Schmiederer D, Pham-Tuan H, Röhring C, Rauh M. Standardized LC-MS/MS based steroid hormone profile-analysis. J Steroid Biochem Mol Biol. 2012;129:129-138. doi: 10.1016/j.jsbmb.2011.12.001.
22. Otto-Duessel M, He M, Jones JO. Tissue-selective regulation of androgen-responsive genes. Endocr Res. 2012;37:203-215. doi: 10.3109/07435800.2012.668254.
23. Mahendroo MS, Cala KM, Hess DL, Russell DW. Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes. Endocrinology. 2001;142:4652-4662. doi: 10.1210/endo.142.11.8510.
24. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blümel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010;142:203-217. doi: 10.1016/j.cell.2010.06.001.
25. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is over-expressed in hormone-refractory prostate cancer. Cancer Sci. 2008;99:81-86. doi: 10.1111/j.1349-7006.2007.00656.x.
26. Windahl SH, Andersson N, Börjesson AE, Swanson C, Svensson J, Movérare-Skrtic S, Sjögren K, Shao R, Lagerquist MK, Ohlsson C. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice. PLoS One. 2011;6:e21402. doi: 10.1371/journal.pone.0021402.
27. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J. 2002;16:1537-1549. doi: 10.1096/fj.02-0138com.
28. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM Jr, Pope HG Jr. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 2010;3:472-476. doi: 10.1161/CIRCHEARTFAILURE.109.931063.
29. Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofschire PJ. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc. 1993;25:1240-1245.
30. Gao XM, Agrotis A, Autelitano DJ, Percy E, Woodcock EA, Jennings GL, Dart AM, Du XJ. Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology. 2003;144:4097-4105. doi: 10.1210/en.2002-0214.
31. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology. 2004;145:951-958. doi: 10.1210/en.2003-0816.
32. Montalvo C, Villar AV, Merino D, García R, Ares M, Llano M, Cobo M, Hurlé MA, Nistal JF. Androgens contribute to sex differences in myocardial remodeling under pressure overload by a mechanism involving TGF-β. PLoS One. 2012;7:e35635. doi: 10.1371/journal.pone.0035635.
33. Rubio-Gayosso I, Ramirez-Sanchez I, Ita-Islas I, Ortiz-Vilchis P, Gutierrez-Salmean G, Meaney A, Palma I, Olivares I, Garcia R, Meaney E, Ceballos G. Testosterone metabolites mediate its effects on myocardial damage induced by ischemia/reperfusion in male Wistar rats. Steroids. 2013;78:362-369. doi: 10.1016/j.steroids.2012.12.004.
34. Tepavčević S, Vojnović Milutinović D, Macut D, Žakula Z, NikolićM, Božić-Antić I, Romić S, Bjekić-Macut J, Matić G, Korićanac G. Dihydrotestosterone deteriorates cardiac insulin signaling and glucose transport in the rat model of polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2014;141:71-76. doi: 10.1016/j.jsbmb.2014.01.006.
35. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2:e000272. doi: 10.1161/JAHA.113.000272.
36. Rauchhaus M, Doehner W, Anker SD. Heart failure therapy: testosterone replacement and its implications. Eur Heart J. 2006;27:10-12. doi: 10.1093/eurheartj/ehi653.
37. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5:315-321. doi: 10.1161/CIRCHEARTFAILURE.111.965632.
38. Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014;306:E433-E442. doi: 10.1152/ajpendo.00592.2013.
39. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A, Cheng J, Lu G, Morris DJ, Castrillon DH, Gerard RD, Rothermel BA, Hill JA. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation. 2006;114:1159-1168. doi: 10.1161/CIRCULATIONAHA.106.637124.
40. Altamirano F, Oyarce C, Silva P, Toyos M, Wilson C, Lavandero S, Uhlén P, Estrada M. Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol. 2009;202:299-307. doi: 10.1677/JOE-09-0044.
41. Vicencio JM, Ibarra C, Estrada M, Chiong M, Soto D, Parra V, Diaz-Araya G, Jaimovich E, Lavandero S. Testosterone induces an intracellular calcium increase by a nongenomic mechanism in cultured rat cardiac myocytes. Endocrinology. 2006;147:1386-1395. doi: 10.1210/en.2005-1139.
42. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003;278:42992-43000. doi: 10.1074/jbc.M306295200.
43. Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55:367-379. doi: 10.4111/kju.2014.55.6.367.
44. Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. J Clin Pharm Ther. 2013;38:405-415. doi: 10.1111/jcpt.12080.